Aslan Pharmaceuticals Limited
(NASDAQ: ASLN)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $2.38 | Change: +0.13 | %Change: +5.87% | Volume: 56,823 |
Open: | $ 2.20 | Volume: | 56,823 | |
---|---|---|---|---|
High: | $ 2.53 | Yield(%) | 0.00 | |
Low: | $ 2.20 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 6.34M | |
EPS ($) | -1.99 | Shares Out: | 22.63M |
% Price Change (last 4 weeks): | -38.12 |
---|---|
% Price Change (last 13 weeks): | -50.70 |
% Price Change (last 26 weeks): | -48.91 |
% Price Change (last 52 weeks): | -92.28 |
% Price Change (year to date): | -93.30 |
Return on Equity (%): | n/a |
---|---|
Return on Assets (%): | -103.06 |
Return on Invested Capital (%): | -127.94 |
Gross Profit Margin (%): | 97.10 |
---|---|
Net Profit Margin (%): | -368.50 |
Operating Profit Margin (%): | -364.46 |
|
|
50-day Moving Average: | $3.28 |
---|---|
200-day Moving Average: | $5.90 |
Avg. Daily Vol. (last 50 days): | 59,802 |
Avg. Daily Vol. (last 200 days): | 61,110 |
52-wk high: | $31.12 |
52-wk low: | $2.17 |
Bid: | $2.27 |
Ask: | $2.45 |
Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which develops novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.
|
Aslan Pharmaceuticals Limited
3 Temasek Avenue 18 Level Centennial Tower Singapore CE 039190 Phone: 65.6817.9598 Fax: n/a http://www.aslanpharma.com |
Earnings (1year) ($): | -1.99 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | -0.76 |
Cash Flow ($): | -2.49 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 0.72 |
Price/Book (x): | n/a |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 1.84 |
---|---|
Current Ratio (x): | 1.84 |
LT Debt/Equity (x): | n/a |
Total Debt/Equity (x): | n/a |